Candesartan for Migraine Prevention:

PHASE2CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

April 9, 2021

Primary Completion Date

April 12, 2024

Study Completion Date

August 8, 2024

Conditions
Migraine
Interventions
DRUG

Candesartan Oral Tablet 8 mg

1 over-encapsulated tablet once daily, containing candesartan 8 mg, for 12 weeks (84 days).

DRUG

Candesartan Oral Tablet 16 mg

1 over-encapsulated tablet once daily, containing candesartan 16 mg, for 12 weeks (84 days).

DRUG

Placebo oral tablet

1 over-encapsulated tablet once daily, containing placebo, for 12 weeks (84 days).

Trial Locations (10)

Unknown

Tartu University Clinics, Tartu

Haukeland University Hospital, Bergen

Nordland Hospital, Bodø

Sørlandet Hospital, Kristiansand

Akershus University Hospital AHUS, Lørenskog

Møre and Romsdal Hospital Molde, Molde

Rikshospitalet University Hospital, Oslo

Ullevål University Hospital, Oslo

University Hospital of North Norway, Tromsø

St Olavs Hospital, Trondheim

All Listed Sponsors
collaborator

Norwegian University of Science and Technology

OTHER

collaborator

Nordlandssykehuset HF

OTHER

collaborator

Molde Hospital

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

Sorlandet Hospital HF

OTHER_GOV

collaborator

University Hospital, Akershus

OTHER

collaborator

Ullevaal University Hospital

OTHER

collaborator

Rikshospitalet University Hospital

OTHER

collaborator

University Hospital of North Norway

OTHER

collaborator

Tartu University Hospital

OTHER

lead

St. Olavs Hospital

OTHER